Nov. 30, 2022 – Artificial intelligence is poised to make clinical trials and drug development faster, cheaper, and more efficient. Part of this strategy is creating “synthetic control arms” that use data to create “simulants,” or computer-generated “patients” in a trial. 

This way, researchers can enroll fewer real people and recruit enough participants in half the time. 

Both patients and drug companies stand to gain, experts say. An advantage for people, for example, is simulants get the standard-of-care or placebo treatment, meaning all people in the study end up getting the experimental treatment. For drug companies unsure of which of their drug…


By prebo

Leave a Reply

Your email address will not be published. Required fields are marked *